Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Bicycle Therapeutics narrowed its Q2 net loss to $50.3 million, or $0.72 per share, down from a loss of $79.0 million a year ago, attributing the improvement to workforce reductions and lower clinical trial costs. The company reported encouraging clinical data, including a 65% unconfirmed overall response rate for zelenectide in the Duravelo-2 trial and the successful first dosing of a patient in a Phase 2 trial for nuzefatide in recurrent pancreatic cancer.
Key figures
- Net Loss
- 50300000
- Revenue
- 629000
- Cash runway
- into 2030
- Ga expenses
- 14000000
- Rd expenses
- 41200000
- Cash position
- 510100000
- Zelenectide pfs months
- 13
- Nuzefatide phase2 dosing
- April 2026
- Zelenectide orr confirmed
- 58%
- Zelenectide orr unconfirmed
- 65%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.